@Attomarker

@Attomarker

@myESMO

@peters_solange

@NeurologyToday

Simona Cristea

@simocristea

The science of #immunotherapy can cure a patient's otherwise incurable cancer.

But sometimes immunotherapy fails completely

Shockingly, we hardly know why.

A meta-analysis of #Genomics & #Transcriptomics in >1,000 immunotherapy-treated patients aims to better understand why🧵

@CellCellPress

This 2021 @CellCellPress paper is one of the best #DataScience #Bioinformatics resources out there for understanding the genetic determinants of response to immune checkpoint inhibitors (ICIs).

cell.com/cell/fulltext/…

Some context:

PD-1 & PD-L1 inhibitors are examples of ICIs.

ICI is a type of immunotherapy that un-blocks the immune system & allows it to mount attacks🤺

It does it by inhibiting checkpoints (s.a. PD-1 & PD-L1): proteins that keep the immune system from attacking its own self

Read 28 tweets

Simona Cristea

@simocristea

@NatureMedicine

#singlecell analysis is revolutionizing medicine and changing the way we look at disease.

New perspective article just out🚨@NatureMedicine reflecting on @humancellatlas: informative for both #singlecell lovers❤️& skeptiks🤔

Let's map out where the field stands & what is next🧵

First, some context.

The genomics single cell field has started out 1-2 decades ago with a huge promise:

"Find the missing link between genes, diseases and therapies. This will bring completely novel therapeutics to the market & cure disease."

The underlying logic is straigtforward:

1. the cell is the main unit of living organisms
⬇️
2. cells break down in disease
⬇️
3. understanding cells helps understand how & why they break
⬇️
4. this helps with engineering new therapeutics
⬇️
5. new therapeutics will cure disease

Read 13 tweets

Jim Jackson

@jimjaxn100

@ashkanshahbandi

Happy to announce our latest publication is online!
rdcu.be/c1f58
Huge effort from @ashkanshahbandi and co authors @Raegan2222 @SelinaSMJ_here @AshlynA_99 @LabMachado @Lorax_Bodyspray @Thesrao
#cancer #breastcancer #Immunotherapy #SABCS2022
a quick 🧵 tweetorial...

@ashkanshahbandi

@ashkanshahbandi was interested in examining why some BC have residual disease after chemo Rx that persists. These tumors tend to be p53 wild type and tend to undergo cell cycle arrest/senescence rather than cell death #chemotherapy #residualdisease

Looking at immune regulatory pathways he found PD-L1 and CD80 were both highly induced in tumors from chemotherapy treated mice. By RNA, many checkpoints were induced in senescent human BC and mouse mammary tumors after chemo (Fig.1)

Read 20 tweets

Simona Cristea

@simocristea

@Nature

New🔥TCR #CRISPR✂️ cancer #immunotherapy paper just out in @Nature by PACT Pharma & UCLA.

Why all the 📸headlines & press coverage?

This small proof-of-concept study can give us a glimpse into the future of cancer therapy.

Let’s unpack the details & relevance of this study👇🧵

@Nature

First things first:

Here’s the link to the paper, which has been made public by @Nature in an unedited form (before official publication), due to its perceived immediate relevance to the research & clinical cancer communities.

nature.com/articles/s4158…

A. The context ✍️ of this work:

Most cancerous lesions have mutations in the 🧬of their cells.

Cancer cells (literally) display small pieces of cellular mutated proteins (called peptides) on their surface.

These peptides, called neoantigens, are important therapeutic targets.

Read 21 tweets

G Curigliano MD PhD

@curijoey

@Roche

Sponsored by @Roche,
I would like to share a Tweetorial about recent important advances in the management of advanced/metastatic triple negative breast cancer (mTNBC)

#Tweetorial #Oncology #Cancer #Diagnosis #TNBC #Immunotherapy #PDL1

TNBC is a challenging disease to treat due to its aggressive behavior, heterogeneity, and the lack of universal actionable targets. mTNBC is commonly diagnosed at a younger age than other BC subtypes and its prognosis is poor, with a median survival of <2 years.

Advanced TNBC can result from recurrence after treatment in the early-stage disease setting, or it may be diagnosed at initial (de novo) presentation

Read 12 tweets

Rafa Argüello

@RafaJArguello

📢 Very 🔥 out of press!

Our paper about #metabolic reprogramming in DC during development and activation.

OPEN ! (enjoy) nature.com/articles/s4146…
#natcomms

DC can 🔥 or🧯adaptive immune responses (IR). Also Metabolism can 🔥 or🧯 IR.

Little "zoom" on this story:👇

🧵

@SCENITHmetab

🤔 What are the metabolic profiles associated to inflammatory🔥 and tolerogenic 🧯👫 monocyte derived DCs?

Tools 🛠️ developed by us @SCENITHmetab (@CIML_Immunology), @felixjhartmann and others allowed us to address those questions.

(SCENITH)

https://twitter.com/RafaJArguello/status/1333804859364052994

@SCENITHmetab

👆
- A dramatic metabolic switch in monocytes one day after they start differentiation (top right).

Also:
How metabolic heterogeneity links to surface markers heterogeneity by #SCENITH (@SCENITHmetab & #scMEP in 🧯or 🔥 conditions

Check the nature.com/articles/s4146…

....

Read 6 tweets

S Blitshteyn MD, Dysautonomia Clinic

@dysclinic

Very happy to share our new study on #immunotherapy in #POTS. We conclude that patients w/ severe, treatment-refractory POTS experienced significant improvement with subcutaneous immunoglobulin or PLEX. Randomized controlled trials are needed. #MedTwitter
link.springer.com/epdf/10.1007/s

Working link here:
nam12.safelinks.protection.outlook.com/?url=https%3A%…

Read 4 tweets

Arun Wiita

@apwiita

@NatureComms

Our latest now out @NatureComms! We use cell surface #proteomics to find new #immunotherapy targets and biomarkers of resistance in #myeloma #mssm. Resource + we identify CCR10 as target & develop natural ligand CAR-Ts. Huge effort led by @idferguson
nature.com/articles/s4146…

@bonellpatinoe

w/informatics & primary sample analysis led by @bonellpatinoe. Wonderful collaboration with @realjimwells @j_eyquem @iamdrdex and our @ucsfcancer myeloma clinical team @ninashah33 @tombmt133 @myelomawolf @sandywong0211

We initially quantified >1000 membrane spanning proteins across myeloma cells and identified some surprising proteins that most distinguish plasma cells vs. B-cell leukemia, along with canonical markers

Read 9 tweets

Vinod BalachandranMD

@TheVinodLab

@Nature

Today, in @Nature, we reveal PART 2 of our investigations on

“What IS going on in long-term survivors of #PancreaticCancer (#PDAC)?”

“Is it REALLY the immune system?”

Well…more evidence here - > nature.com/articles/s4158…

Thread below [1/30]

@Nature

In 2017, we reported in @Nature here -> nature.com/articles/natur… -> that primary tumors of long-term survivors of #PDAC had ~12x more activated CD8 T cells vs. short-term survivors. Now, others had reported this before - but we wanted to know:

“What are the antigens?”

Here, the prevailing belief was:

#PDAC has few mutations -> even fewer mutation-derived neoantigens -> neoantigens are unlikely T cell antigens in #PDAC.

But we thought: despite #PDAC’s few mutations, mutation-derived neoantigens may still be T cell antigens in #PDAC survivors

Read 31 tweets

Livnat Jerby

@LivnatJerby

@NatureBiotech

Excited to share that our @NatureBiotech paper with Aviv Regev on Multicellular Programs (MCPs) is now out with a fully automated data-driven method to identify MCPs from #singlecell or spatial data #behindthepaper: go.nature.com/3iQ8fgW nature.com/articles/s4158… (1/19)

Gene programs are often studied within a cell, with each cell considered an “independent entity”. However, cells from the same niche/tissue/organism are not independent, but share external signals, genetic background/lineage, and can directly impact one another. (2/19)

Here we define “Multicellular Programs (MCPs)” as different sets of genes working in concert across different cell types. (3/19)

Read 19 tweets

Saeed Esmaili MD/PhD

@Ses_ma_ili

https://twitter.com/biorxiv_sysbio/status/1515390223940784131

Do Bone Marrow Haematopoietic Stem and Progenitor Cells (#stemcells) influence #fattyliver, Core Liver Networks, and liver cancer?

Very happy to share our findings in this (5 min read) Tweetorial🧵
More details on bioRxiv:

https://twitter.com/biorxiv_sysbio/status/1515390223940784131

#livertwitter

@CellSystemsCP

2. In our previous publication in @CellSystemsCP, we used network analysis (#WGCNA) to identify the preserved liver networks (Core-Modules) between species and screened for their genetic regulators (module-eQTLs).
Infographic by Misaki Ouchida:
misakiouchida.com

@CellRepMed

3. Here you can find a concise review/commentary on our previous paper on core liver networks in @CellRepMed
sciencedirect.com/science/articl…

Read 22 tweets

Mat Legut, PhD

@MatLegut

@nature

Really chuffed to share our latest work from Sanjana Lab out in @nature today (nature.com/articles/s4158…).

We tested >12,000 genes to find positive regulators of T cell proliferation to be used for next-gen #immunotherapies.

A thread...

(2/28) T cell therapies have shown the potential to cure patients from #cancer – but even in B cell cancers, relapses outnumber cures… One of the problems is limited T cell persistence. #celltherapy #CARTcell

(3/28) We wanted to find new genes (including genes never expressed in T cells) that could improve T cell persistence. Now, the question was: should we use #crispr activation or directly deliver target genes on a #lentivirus?

Read 30 tweets

Jesus Corria-Osorio

@CorriaJesus

@CoukosGeorge

Delighted to share our paper, biorxiv.org/content/10.110… . Huge thanks to @CoukosGeorge for the opportunity as well as all our collaborators, @carmonation. A summary of our main findings:

@CoukosGeorge

Orthogonal combinatorial T-cell engineering overcomes homeostatic barriers to engraftment, reprograms TILs as well as the tumor microenvironment and mediates solid tumor regression in the absence of preconditioning or systemic cytokine support @CoukosGeorge, @carmonation

As a proof of principle of orthogonal T-cell engineering, here we successfully combined two main secreted components: an IL-2 variant binding to b/g but not IL-2Ra (promote T-cell stemness), together with the pro-inflammatory alarmin IL-33.

Read 13 tweets

GAVNet

@GAValueNetwork

Daily Bookmarks to GAVNet 02/08/2022
greeneracresvaluenetwork.wordpress.com/2022/02/08/dai…

Pandemic Wealth Disparities Expose Inequality Of Digital Economy
noemamag.com/the-pandemic-e…
#PandemicResponse, #WealthDisparities, #ProductivityGains, #DigitalEconomy

https://twitter.com/nntaleb/status/1490402495704834050

Nassim Nicholas Taleb on Twitter

https://twitter.com/nntaleb/status/1490402495704834050

#disinformation, #WordMeaning, #WordUsage

Read 20 tweets

Lukas Orre

@LM_Orre

@NatureCancer

Very happy to present our #proteomics analysis of #lungcancer published today @NatureCancer!🙂
Here’s a walk-through: #MassSpec analysis covering almost 14k proteins in 141 NSCLC tumors revealed 6 proteome subtypes with distinct biology. 1/6
rdcu.be/cBOtU

#NSCLC proteome subtypes are driven by histology, growth pattern, immune cell infiltration, driver mutations, oncogenic pathways, and cell types, suggesting potential clinical value for treatment stratification and #PrecisionMedicine. 2/6

Unexpectedly, #proteogenomics analysis revealed that high neoantigen burden was linked to global hypomethylation, and that complex neoantigens mapping to genomic regions normally not active in lung were produced in immune-cold subtypes. 3/6

Read 6 tweets

BlackInImmuno

@BlackInImmuno

Starting #UnsungHeroesImmuno. Did you know about Onesimus and his knowledge of variolation? 1/

#UnsungHeroesImmuno What about Dr. William Augustus Hinton and his work with syphilis? 2/

#UnsungHeroesImmuno We also have Drs. Louis Tompkins Wright and Jane Cook Wright, a father-daughter pair that changed the field of oncology. 3/

Read 14 tweets

Pavan Bachireddy

@pbachi

@elhamazizi

1/ Excited to share how T cell therapies kill #leukemia!! multi-omics + new #computational #singlecell tools for longitudinal analysis 👉unexpected answer! cell.com/cell-reports/f…

*👏* @elhamazizi! 🙏 @dpeer Cathy Wu @MDAndersonNews @CPRITTexas @ColumbiaBME @sloan_kettering

2/ We studied donor lymphocyte infusion (DLI) - an #Immunotherapy for relapsed #leukemia after #BMT & the #og of #celltherapy. Previously, we showed DLI reversed T cell exhaustion - but didn't know why/how/which T cells were responsible...
ashpublications.org/blood/article/…

3/ To address these ?'s, we modeled intraleukemic T cell dynamics by integrating longitudinal, multimodal data from ~100K T cells (!) during response (R) or resistance (NR: nonresponder) to DLI.

Read 18 tweets

Shruti Gupta

@ShrutiGkidney

@DavidLeaf9

*NEW ARTICLE*
What does a nephrologist need to know about immune checkpoint inhibitor-associated AKI (ICPi-AKI)?@DavidLeaf9 #Thread
my first #tweetorial with help from @kdjhaveri
jitc.bmj.com/content/9/10/e… (1/11)

Why does it matter? ICPi-AKI can lead to:
*Discontinuation of ICPi therapy
*Irreversible loss of kidney function
*Prolonged courses of immunosuppression (2/11)

We conducted a multicenter study of 429 patients with ICPi-AKI from 30 sites across 10 countries, along with 429 control patients who received ICPis contemporaneously but did not develop ICPi-AKI. This is the largest study to date on ICPi-AKI (3/11)

Read 11 tweets

Kenar Jhaveri

@kdjhaveri

@Kidney_Int

1)Tweetorial: Immune check point inhibitor related electrolyte disorders short letter @Kidney_Int kidney-international.org/article/S0085-… @renalmyeloma and Vipul Sakhiya - the FDA adverse reporting system.

@MayoClinicNeph

2) Electrolytes were first mentioned @MayoClinicNeph as most common being hypocalcemia pubmed.ncbi.nlm.nih.gov/29762725/

@BWHKidney

3)Hyponatremia and other disorders were summarized in a single center study @BWHKidney @BetterCallSeeth @MegSise pubmed.ncbi.nlm.nih.gov/33374011/

Read 10 tweets

#TumorBoardTuesday

@TumorBoardTues

@DrBonillaOnc

#TumorBoardTuesday
💥Wow - this week was TOO much‼️

A🗣️on TMB-high #PancreaticCancer & #Immunotherapy by @DrBonillaOnc

AND our 1st pt-directed🗣️led by @HPolymenis and @StephenVLiu

👉Don’t forget your🆓#CME credit-answer 3 quick❓
Here's the postest🔗
surveymonkey.com/r/6JVHCSG

twitter.com/i/events/13999…

#TumorBoardTuesday
Thursday Case🎀
(Case from 06/01 and 06/02/21)

We discussed #PancreaticCancer and:
✅Cynicism/Nihilism
✅The importance of multi-D care
✅1st line Tx
✅🧬Testing
✅#Immunotherapy

We captured as much as we could in this moment:
twitter.com/i/events/13999…